The outcomes of a standardized protocol for extracorporeal mechanical circulatory support selection-left ventricular challenge protocol

• Published in: Journal of artificial organs Vol. 27; no. 4; pp. 358 - 367
• Main Authors: Tadokoro, Naoki, Koyamoto, Tetsuya, Tonai, Kohei, Yoshida, Yuki, Hirahsima, Koudai, Kainuma, Satoshi, Kawamoto, Naonori, Minami, Kimito, Nishioka, Hiroshi, Yasumasa, Tsukamoto, Fujita, Tomoyuki, Fukushima, Satsuki
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.12.2024; Springer Nature B.V
• Subjects: Adult; Aged; Aorta; Biomedical Engineering and Bioengineering; Cardiac Surgery; Cardiomyopathy; Circulatory system; Congestive heart failure; Dilated cardiomyopathy; Dissection; Doxorubicin; Extracorporeal membrane oxygenation; Extracorporeal Membrane Oxygenation - methods; Female; Heart diseases; Heart failure; Heart Failure - surgery; Heart Failure - therapy; Heart-Assist Devices; Humans; Implantation; Male; Medicine; Medicine & Public Health; Middle Aged; Myocardial infarction; Myocarditis; Nephrology; Original Article; Oxygenation; Retrospective Studies; Tachycardia; Treatment Outcome; Weaning; Heart failure; Central ECMO; Ventricular-assist device; Protocol
• ISSN: 1434-7229; 1619-0904; 1619-0904
• DOI: 10.1007/s10047-023-01427-7

There are no criteria for surgical mechanical circulatory system (MCS) selection for acute heart failure. Since 2021, we have utilized cardiopulmonary bypass system to assess patients’ heart and lung condition to inform surgical MCS selection. we aimed to retrospectively analyze the outcomes of treatments administered using our protocol. We analyzed the data of 19 patients who underwent surgical MCS implantation. We compared patients’ characteristics across the biventricular-assist device (BiVAD), central Y-Y extracorporeal membrane oxygenation (ECMO), central ECMO, and left VAD (LVAD) systems. Patients' diagnoses included fulminant myocarditis (47.4%), dilated cardiomyopathy (21.1%), acute myocardial infarction (15.8%), infarction from aortic dissection (5.3%), doxorubicin-related cardiomyopathy (5.3%), and tachycardia-induced myocarditis (5.3%). Eight patients (42.1%) underwent LVAD implantation, 1 (5.2%) underwent central ECMO, 4 (21.1%) underwent BiVAD implantation, and 6 (31.6%) underwent central Y-Y ECMO. 48 h after surgery, both the pulmonary arterial and right atrial pressures were effectively controlled, with median values being 19.0 mmHg and 9.0 mmHg, respectively. No patients transitioned from LVAD to BiVAD in the delayed period. Cerebrovascular events occurred in 21.1%. Successful weaning was achieved in 11 patients (57.9%), and 5 patients (26.3%) were converted to durable LVAD. Two-year cumulative survival was 84.2%. Our protocol showed good results for device selection in patients with heart failure, and device selection according to this protocol enabled good control of the pulmonary and systemic circulations.